OTTAWA, Nov. 1, 2011 /CNW/ - Rx&D President Russell Williams made the following statement to
complement Merck Canada's announcement of the investment of $33.2
million to modernize its Pointe Claire Manufacturing facility.
"This investment has resulted in the expansion of the plant and
installation of state-of-the-art production equipment, increasing the
facility's efficiency and competitiveness internationally, while
preserving local jobs. In total, $20 million of the overall investment
went toward the purchase of goods and services from Quebec suppliers.
The Pointe Claire plant employs 264 people and has been confirmed as a
Centre of Excellence for manufacturing liquids, ointments and creams.
"The chance to make a significant contribution to the lives of Canadians
and improve patient health and quality of life through research and
innovation is what motivates Merck Canada and all those active in the
life science community.
"It is by working together that we can consolidate the position of
Canada as a potential world leader in the provision of health care
solutions to people across the country and throughout the world.
Creating a favorable environment by improving Canada's intellectual
property and access regimes would greatly facilitate the attraction of
additional life sciences investments in Canada by the innovative
pharmaceutical sector that would benefit Canadian patients and the
Rx&D is the association of leading research-based pharmaceutical
companies dedicated to improving the health of Canadians through the
discovery and development of new medicines and vaccines. Our community
represents 15,000 men and women working for 50 member companies and
invests more than $1 billion in research and development each year to
fuel Canada's knowledge-based economy. Guided by our Code of Ethical
Practices, our membership is committed to working in partnership with
governments, healthcare professionals and stakeholders in a highly
Today's Merck is working to help the world be well. Merck is a global
health care leader with a diversified portfolio of prescription
medicines, vaccines, consumer and animal health products. In Canada,
Merck markets over 530 pharmaceutical, consumer and animal health
products and is a leader in a broad range of areas such as cardiology,
immunology, infectious diseases, respiratory, vaccines, women's health
and sun care. It is also focused on expanding offerings in other areas,
including virology, oncology and diabetes.
Merck is one of the top R&D investors in Canada, with an investment of
$78.6 million in 2010. Merck also has a large manufacturing facility in
Québec dedicated to the annual production of some 35 million units
including the Claritin® and Aerius® brands. Based in Montreal, Quebec,
Merck employs over 1,400 people across Canada. For more information
about our operations in Canada, visit www.merck.ca.
SOURCE CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES (RX
For further information: